Mucopolysaccharidosis I (MPS I)

This is a group of rare genetic disorders. It happens when the body can't break down certain sugars called glycosaminoglycans. This causes these sugars to build up in various parts of the body, leading to different health problems.

Condition

What people with Mucopolysaccharidosis I (MPS I) report

Every report comes from a Lived member, sent anonymously.

Have you tried Enzyme Replacement Therapy for Mucopolysaccharidosis I (MPS I)?

NameHow it went

About Mucopolysaccharidosis I (MPS I)

What It Is

Mucopolysaccharidosis type I (MPS I) is a rare inherited condition in which the body cannot break down certain long sugar molecules called glycosaminoglycans. Normally an enzyme called alpha-L-iduronidase clears them inside cells. Without enough of that enzyme, the molecules build up gradually in the bones, joints, airway, heart, eyes, liver and spleen, and in some people the brain. The result is a condition that affects many parts of the body and tends to worsen over time. MPS I runs along a spectrum. In the severe form, long known as Hurler syndrome, babies look healthy at birth, but problems such as hernias, frequent colds and ear infections, a curved lower spine and coarsening facial features appear during the first year or two. Growth slows, joints stiffen, and learning and development fall further behind over time. The attenuated (milder) forms, once called Hurler-Scheie and Scheie syndrome, usually show up between ages 3 and 10. Joint stiffness, heart valve problems, hearing loss, clouding of the cornea (the clear front of the eye) and breathing problems during sleep are common, while thinking may be unaffected or only mildly affected. Knowing which form a person has is central, because it shapes treatment.

Causes & Risk Factors

MPS I is caused by changes in both copies of the IDUA gene (short for iduronidase), which carries the instructions for the missing enzyme. It is inherited in an autosomal recessive pattern: each parent usually carries one changed copy without having symptoms. When both parents are carriers, each pregnancy has a 25% (one in four) chance of a child with MPS I, a 50% chance of a child who is a carrier, and a 25% chance of a child who neither has the condition nor carries it. Nothing a parent did during pregnancy causes MPS I, and lifestyle does not bring it on. The specific gene changes help predict whether the disease will be severe or attenuated, which is one reason genetic testing matters. Severe MPS I occurs in roughly 1 in 100,000 births, and the attenuated form is rarer still.

How It's Diagnosed

Because early signs such as hernias and repeated infections are common in healthy children, MPS I is often suspected only when several features appear together or when x-rays show the typical bone changes. A urine test can show high levels of glycosaminoglycans, which points toward a mucopolysaccharidosis but does not identify which one. The diagnosis is confirmed by a blood test showing very low activity of the alpha-L-iduronidase enzyme, along with genetic testing that finds changes in both copies of the IDUA gene. MPS I has been added to the US recommended newborn screening panel, but each state decides whether to screen for it, so not every baby is tested. A positive screen leads to confirmatory testing. Screening and early tests cannot always tell whether a baby will develop the severe or attenuated form, so specialists combine genetic results with close follow-up. When a child is diagnosed, brothers and sisters are often tested too, since starting treatment before damage builds up gives the best results.

Treatment Options

There is no cure for MPS I, but two treatments replace the missing enzyme and can change the course of the disease, and timing matters for both. For children with the severe form, a hematopoietic stem cell transplant (a bone marrow or blood stem cell transplant from a healthy donor) is the standard treatment. The donor cells keep making the enzyme, including in the brain. Expert groups prefer transplant for children with severe MPS I diagnosed before about age 2.5, because it is the only treatment shown to preserve thinking and development, and results are better the earlier it happens. Transplant also improves survival, growth, hearing and breathing, but it does less for bones, joints, corneas and heart valves. It carries serious risks, including graft-versus-host disease (donor cells attacking the body) and death, which is why it is mainly reserved for the severe form. Enzyme replacement therapy uses laronidase (Aldurazyme), a manufactured version of the missing enzyme given as an intravenous infusion once a week, with each infusion usually taking about 3 to 4 hours. It is approved for the severe and Hurler-Scheie forms and for Scheie syndrome with moderate to severe symptoms. In people with attenuated disease it can shrink an enlarged liver, improve growth and joint movement, slow breathing decline and improve sleep apnea. It does not reach the brain, so it is not expected to protect thinking. Many children start it at diagnosis while awaiting transplant. Laronidase carries a boxed warning for serious allergic reactions, so infusions are given where staff can monitor closely and treat a reaction, often after a premedication such as an antihistamine. Much of care targets specific problems: surgery to relieve carpal tunnel syndrome (nerve pressure at the wrist) or spinal cord compression, joint and heart valve replacement, removal of tonsils and adenoids, ear tubes and hearing aids, CPAP (a machine that keeps the airway open during sleep), corneal transplant, physical therapy and educational support.

What to Expect

MPS I is a lifelong condition, and its outlook varies widely with the form and the timing of treatment. Without treatment, severe MPS I usually leads to death within the first ten years, most often from heart and breathing problems. Transplant has allowed many children with the severe form to live much longer, often with some lasting learning difficulty and ongoing bone and joint problems. People with attenuated MPS I commonly live into adulthood; some have a near-normal lifespan with significant joint, heart or breathing disability, while others have more serious complications earlier. Learning or emotional difficulties can appear later even in milder forms. Daily life usually revolves around a lot of medical care. Weekly infusions, regular visits with a team that may include genetics, orthopedics, cardiology, lung and sleep medicine, ear, nose and throat, eye care and developmental specialists, and checkups every 6 to 12 months with tests such as heart ultrasounds, hearing tests, sleep studies and nerve studies are typical. Surgery is common over the years, and anesthesia carries special risk because the airway can be narrow and the neck unstable, so it should be planned at a center experienced with MPS. Sunglasses or brimmed hats can ease glare from corneal clouding. Families often benefit from school accommodations, genetic counseling and connection with MPS support organizations.

When to Seek Help

Ask for an evaluation if a child has several features that could fit MPS I, such as hernias with stiff joints, a curved spine, slowing growth or coarsening facial features, or if a relative has been diagnosed. For someone with MPS I, raise new snoring or pauses in breathing during sleep, worsening hearing or vision, hand numbness or tingling, or rapid growth of an infant's head at the next visit. Contact the care team promptly about new weakness, reduced activity or endurance, changes in walking, or loss of skills, since these can signal spinal cord compression or other progression. Serious allergic reactions to laronidase usually begin during an infusion but can appear up to three hours afterward; trouble breathing, noisy breathing, widespread hives or fainting after an infusion needs emergency care, so call 911.

Questions to Ask Your Doctor

  1. 1.Does this look like the severe or attenuated form, and how certain can we be at this point?
  2. 2.Is a stem cell transplant an option, and how do its likely benefits and risks compare with weekly enzyme infusions?
  3. 3.Which specialists should be on the care team, and what checks are due in the next year?
  4. 4.What should any surgeon or anesthesia team know before a procedure?
  5. 5.Should other family members have carrier or diagnostic testing, and what are the options for future pregnancies?

Last reviewed • Oct 2026

Educational content, not medical advice.